医疗器械公司Merit Medical一亿美元收购BD医疗、巴德医疗活检资产

据外媒消息，MeritMedical（NYSE: MMSI）近日表示，以1亿美元收购BD医疗(NYSE:BDX) 和 巴德医疗(NYSE: BCR)的软组织活检资产（据反垄断法规定，BD医疗和巴德公司需要通过剥离旗下活组织检查业务来完成他们240亿美元的合并）。

这笔交易包括了BD医疗的软组织针芯穿刺活检生产线，也包括了巴德医疗的Aspira胸腔积液引流和腹腔引流系统。

Merit Medical的主席兼首席执行官FredLampropoulos表示：我们相信此次收购有着完美的契合度，这些产品都是建立在非常成熟的基础上，并与Merit的CorVocet全核心活组织检查系统和我们最近收购的骨活组织检查产品有互补性。Fred同时提到，我们相信这次交易将提供互补的高利润产品，增加我们现有设备的使用，市场扩张机会，增加利润和我们现有的销售力量的使用。

据估计，在2018财年，该公司的年度收入将增加4200万美元至4800万美元，在调整后每股收益为10至19美元。

Merit Medical成立于1987年，总部位于犹他州的南约旦，在爱尔兰的戈尔韦、德克萨斯州安格尔顿及弗吉尼亚州的里士满设有生产工厂，均获得ISO13485认证，是一家医疗器械生产企业，生产心脏及放射介入手术中使用的器械。产品线包括介入充盈装置及其附件、诊断和治疗性导管及导丝、一次性压力监测设备、造影剂管理系统、非血管性支架、溶栓导管及注射器和针具等。 

MeritMedical (NSDQ:MMSI) said today that it agreed topay $100 million for soft tissue biopsy assets Becton Dickinson (NYSE:BDX) and C.R. Bard (NYSE:BCR) need to sell to consummatetheir $24 billion merger.

The deal coversBD’s Achieve and Temno biopsy systems and Tru-Cut biopsy needles, plusBard’s Aspira pleural effusion drainage and peritoneal drainage systems,South Jordan, Utah-based Merit said.

 “We believe this is a perfect fit for Merit,”chairman & CEO Fred Lampropoulos said in prepared remarks. “These productsare well established with an installed base and complement Merit’s CorVocetfull core biopsy system and our recently-acquired bone biopsy products.

 “There are also a number of markets in whichMerit has direct representation that will be expanded to include the acquiredproducts, as well as new markets which we plan to develop,” Lampropoulos said.“In summary, we believe this transaction will provide complementary high-marginproducts, increased use of our existing facilities, market expansionopportunities, accretive margins, profits and our existing sales forceutilization.”

“Today’s announcement of ourintent to divest two product lines is another step forward in the regulatoryreview process of BD’s planned acquisition of Bard,” added BD chairman & CEO VincentForlenza. “We continue to expect that the BD and Bard transaction will close inthe fourth calendar quarter of 2017, subject to customary closing conditionsand additional regulatory approvals, including the U.S. Federal TradeCommission and other regulatory bodies.”

Merit said it plans to financethe acquisitions with an existing credit revolver. The biopsy assets areexpected to add $42 million to $48 million in annual revenues and 10¢ to19¢ in adjusted earnings per share during fiscal 2018.

In September BD and Bard agreed to unspecified concessions to address Europeananti-trust concerns, after Bard shareholders overwhelmingly approved the $24 billionmerger inAugust. The $317-per-share deal, which was announced last April, is expected to close duringthe fourth quarter, the companies have said. In June, the FTC asked for more information on themerger,adding 30 days to the timeline for closing the deal.